Protagonist Therapeutics, Inc. Company Profile
Protagonist Therapeutics is a US incorporated biotechnology company pursuing the discovery and development of disulfide rich peptides (DRPs) as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available. DRPs are a proven chemical class of drugs with numerous examples of orally stable and injectable NCEs on the market and in various stages of clinical development. The company has a validated technology platform well suited to exploit the DRP scaffold class. It comprises of a purposefully built computational design environment, directed evolution approaches to prepare millions of molecules via phage libraries, and classical small molecule medicinal chemistry type analoging and SAR development.
News Articles
Protagonist secures $14 million in series B
Protagonist Therapeutics Inc. (Redwood City, Calif.) secured $14 million in a tranched series B round led by new investor Johnson & Johnson Development Corp. Existing investors Lilly Ventures and Star...
It takes one to know one. That’s the road that Protagonist Therapeutics Inc. has taken in forging alliances with other small companies focused on developing peptide therapeutics, instead of taking t...
Zealand, Protagonist to develop peptide drug
Zealand Pharma and Protagonist Therapeutics have joined forces to identify,optimise and develop disulfide-rich peptides (DRPs) with the therapeutic potential to provide better treatment for patients i...
Protagonist Pulls in $14M, Led by J&J, For Peptide Pills
Not many companies know how to make peptide molecules that can be packaged in a pill, but Menlo Park, CA-based Protagonist Therapeutics just got a vote of confidence that it can pull off that nifty li...
[Protagonist Therapeutics] closes $9mm Series A round
Peptide drug developer [Protagonist Therapeutics Inc.] has closed a two-tranche Series A financing, raising $9mm from Lilly Ventures, Starfish Ventures, Queensland BioCapital Fund, and the [University...
Protagonist Therapeutics names chief scientific officer
Protagonist Therapeutics has appointed David Y. Liu, Ph.D., chief scientific officer. With 26 years of biotechnology industry experience, Liu is a former vice president of research and a corporate off...
Series B brings in $14mm for [Protagonist Therapeutics]
[University of Queensland] spin-off [Protagonist Therapeutics Inc.] (developing peptides) raised $14mm in its Series B financing led by first-time backer Johnson & Johnson Development Corp., which add...
[Ironwood], [Protagonist] establish peptide discovery/development deal
Gastrointestinal disease-focused [Ironwood Pharmaceuticals Inc.] and start-up [Protagonist Therapeutics Inc.] (injectable and oral peptide drugs) have announced a collaboration to discover and develop...
Drugs and Medications
None
PubMed Articles
Tracking spatial information during reading: a cue-based process.
The goal of the present set of experiments was to examine whether a cue-based mechanism could account for how, and under what conditions, spatial information is tracked. In five experiments, reading t...
A narrative experience can partly depend on how a narrative ends or concludes. This study examined prevention effects of personal drug use narratives varying by type of ending and gender of protagonis...
Whom to ask for help? Children's developing understanding of other people's action capabilities.
We often rely on other people's help to accomplish tasks and to attain goals. People, however, differ in their physical action capabilities. Some persons are therefore better able to provide help than...
Medicinal chemists synthesize arrays of molecules by attaching functional groups to scaffolds. There is evidence suggesting that some scaffolds yield biologically active molecules more than others, th...
Two new bidentate ligands (1 and 2) with bicyclic guanidine moieties were synthesized and attached to a Ru(II)(bpy)(2) core (bpy = 2,2'-bipyridine) to afford complexes 3 and 4, which were characterize...
Clinical Trials
None
Companies
Ironwood Pharmaceuticals, Inc. & Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a privately held biotechnology company pursuing the discovery and development of disulfide rich peptides (DRPs) as well differentiated alternati...
Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a US incorporated biotechnology company pursuing the discovery and development of disulfide rich peptides (DRPs) as well differentiated alternatives to...
Ironwood Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Ironwood is located in Cambridge, Mass....
More Information about "Protagonist Therapeutics, Inc." on BioPortfolio
We have published hundreds of Protagonist Therapeutics, Inc. news stories on BioPortfolio along with dozens of Protagonist Therapeutics, Inc. Clinical Trials and PubMed Articles about Protagonist Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Protagonist Therapeutics, Inc. Companies in our database. You can also find out about relevant Protagonist Therapeutics, Inc. Drugs and Medications on this site too.
